Cartesian Therapeutics (RNAC) Return on Sales (2016 - 2025)
Historic Return on Sales for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to 43.18%.
- Cartesian Therapeutics' Return on Sales fell 44200.0% to 43.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 76.75%, marking a year-over-year decrease of 723900.0%. This contributed to the annual value of 1.99% for FY2024, which is 64600.0% up from last year.
- Per Cartesian Therapeutics' latest filing, its Return on Sales stood at 43.18% for Q3 2025, which was down 44200.0% from 67.33% recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Return on Sales ranged from a high of 31.99% in Q4 2024 and a low of 67.33% during Q2 2025
- Over the past 5 years, Cartesian Therapeutics' median Return on Sales value was 0.73% (recorded in 2021), while the average stood at 8.9%.
- In the last 5 years, Cartesian Therapeutics' Return on Sales skyrocketed by 557800bps in 2024 and then plummeted by -677700bps in 2025.
- Cartesian Therapeutics' Return on Sales (Quarter) stood at 0.41% in 2021, then decreased by -14bps to 0.35% in 2022, then tumbled by -6880bps to 23.79% in 2023, then skyrocketed by 234bps to 31.99% in 2024, then plummeted by -235bps to 43.18% in 2025.
- Its last three reported values are 43.18% in Q3 2025, 67.33% for Q2 2025, and 18.07% during Q1 2025.